A Study Evaluating the Treatment Selection and Outcome When Changing Antipsychotic Treatment in Schizophrenic Patients
NCT00999895 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 574
Last updated 2011-02-01
Summary
The purpose of the study is to evaluate the outcome of treatment switch defined as an improvement in CGI-CB scale (Clinical Global Impression - Clinical Benefit).
Conditions
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Panagiotis Pontikis, Dr. · Marketing Company Medical and Regulatory Affairs Director, AstraZeneca S.A. Greece
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2009-10-31
- Primary Completion
- 2010-09-30
- Completion
- 2010-09-30
Countries
- Greece
Study Locations
More Related Trials
-
A Trial to Assess the Antipsychotic Efficacy of ITI-007
NCT02282761 ·Status: COMPLETED ·Phase: PHASE3
-
Safety, Tolerability and Pharmacokinetics of AUT00206 in Patients With Schizophrenia, and Also Explores the Effects of AUT00206 on Relevant Central Biomarkers.
NCT03164876 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy of an Early Antipsychotic Switch in Case of Poor Initial Response to the Treatment of Schizophrenia
NCT01029769 ·Status: COMPLETED ·Phase: NA
-
Proof of Concept Study of Cognitive Improvement in Patients With Schizophrenia
NCT00528905 ·Status: COMPLETED ·Phase: PHASE2
-
The Study of Atypical Antipsychotics-induced Metabolic Disturbances
NCT00937755 ·Status: COMPLETED
-
An Extension Study of Safety and Tolerability of SEP-363856 in Adult Subjects With Schizophrenia
NCT02970929 ·Status: COMPLETED ·Phase: PHASE2
-
A Non-Interventional Study of Patients With Persistent Symptoms of Schizophrenia to Describe Medical Resource Utilization and Burden of Illness
NCT01959659 ·Status: COMPLETED
-
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
NCT04092686 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Psychopharmacotherapy in Patients With Schizophrenia or Bipolar Disorders
NCT00330226 ·Status: UNKNOWN
-
Study to Asses Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of AZD0328 in Patients With Schizophrenia
NCT00669903 ·Status: TERMINATED ·Phase: PHASE2
-
Study of Mental Care in Spain
NCT00824031 ·Status: COMPLETED
-
Effects of Eltoprazine on Cognitive Impairment Associated With Schizophrenia (CIAS) in Adults
NCT01266174 ·Status: COMPLETED ·Phase: PHASE2
-
NIS to Observe Improvement in Global Assessment of Functioning in Patients With Schizophrenia
NCT00833456 ·Status: COMPLETED
-
Enhancing the Prospective Prediction of Psychosis
NCT00291200 ·Status: COMPLETED
-
Early Medication Discontinuation and Long-term Clinical Outcome in FEP
NCT01926340 ·Status: COMPLETED
-
A Study of the Safety, PK, and Exploratory Efficacy of SP-624 in Acutely Psychotic Adult Subjects With Schizophrenia
NCT04510298 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluation of the Antipsychotic Efficacy of Cannabidiol in Acute Schizophrenic Psychosis
NCT00628290 ·Status: COMPLETED ·Phase: PHASE2
-
Double Blind, Randomized, 3 Week Inpatient Study To Evaluate The Safety & Efficacy Of PF-02545920 Compared With Placebo
NCT00570063 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Assess the pharmacoMRI Effects of AUT00206 in Healthy Males
NCT02935725 ·Status: COMPLETED ·Phase: PHASE1
-
Long-term Extension Trial of Asenapine in Subjects With Schizophrenia (Study P06125)
NCT01142596 ·Status: COMPLETED ·Phase: PHASE3
-
Study of ALTO-101 in Patients With Schizophrenia
NCT06502964 ·Status: RECRUITING ·Phase: PHASE2
-
Administrating Oxytocin to Treat Treatment Schizophrenia and Schizo-affective Patients
NCT01598623 ·Status: UNKNOWN ·Phase: PHASE2
-
The Benefit of Minocycline on Negative Symptoms in Schizophrenia: Extent and Mechanisms
NCT02928965 ·Status: COMPLETED ·Phase: PHASE2
-
Spanish Validation of Tool Questionnaire to Assess Patients´Perception About Antipsychotic Treatment
NCT00692133 ·Status: COMPLETED
-
Study to Evaluate the Efficacy and Safety of GSK239512 in Schizophrenia
NCT01009060 ·Status: COMPLETED ·Phase: PHASE2